Pub Date : 2019-07-03DOI: 10.1080/24750573.2019.1637040
Burcu Serim Demirgören, A. Özbek, Nüket Göçmen Karabekir, Bari Ay, Serkan Turan, G. Yonguc, S. Karabekir, A. I. Polat, A. S. Hiz, Özlem Gencer Kıdak
ABSTRACT OBJECTIVE Recent data from the literature have recognized the importance of cerebellum in bipolar disorder. Brain imaging studies focusing on cerebellar volumetric changes in bipolar disorder demonstrated controversial data. The aim of this study is to investigate whether there is any difference between early-onset bipolar cases and healthy controls regarding cerebellar volumetric measurements. METHODS Patients with bipolar I disorder were compared to healthy controls in terms of total cerebellar volume, volumes of the right and left cerebellar hemispheres, and cerebellar volumetric asymmetry. All the sociodemographic, clinical data, and magnetic resonance image scans were collected retrospectively. Cerebellar volumes were evaluated using the stereological method. Asymmetry indices were calculated subsequently. RESULTS We recruited 10 bipolar I cases and 10 healthy controls. There were no statistically significant differences between the bipolar and the control groups for total cerebellar volumes, volumes of right and left cerebellar hemispheres, and cerebellar asymmetry indices. CONCLUSION Future studies focusing on cerebellar changes in early-onset bipolar disorder should include large case and control series and designed as follow-up studies for being able to determine the chronic effects of the illness on cerebellar volumes.
{"title":"Cerebellar volumes in early-onset bipolar disorder: a pilot study of a stereological measurement technique","authors":"Burcu Serim Demirgören, A. Özbek, Nüket Göçmen Karabekir, Bari Ay, Serkan Turan, G. Yonguc, S. Karabekir, A. I. Polat, A. S. Hiz, Özlem Gencer Kıdak","doi":"10.1080/24750573.2019.1637040","DOIUrl":"https://doi.org/10.1080/24750573.2019.1637040","url":null,"abstract":"ABSTRACT OBJECTIVE Recent data from the literature have recognized the importance of cerebellum in bipolar disorder. Brain imaging studies focusing on cerebellar volumetric changes in bipolar disorder demonstrated controversial data. The aim of this study is to investigate whether there is any difference between early-onset bipolar cases and healthy controls regarding cerebellar volumetric measurements. METHODS Patients with bipolar I disorder were compared to healthy controls in terms of total cerebellar volume, volumes of the right and left cerebellar hemispheres, and cerebellar volumetric asymmetry. All the sociodemographic, clinical data, and magnetic resonance image scans were collected retrospectively. Cerebellar volumes were evaluated using the stereological method. Asymmetry indices were calculated subsequently. RESULTS We recruited 10 bipolar I cases and 10 healthy controls. There were no statistically significant differences between the bipolar and the control groups for total cerebellar volumes, volumes of right and left cerebellar hemispheres, and cerebellar asymmetry indices. CONCLUSION Future studies focusing on cerebellar changes in early-onset bipolar disorder should include large case and control series and designed as follow-up studies for being able to determine the chronic effects of the illness on cerebellar volumes.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"25 1","pages":"293 - 297"},"PeriodicalIF":0.7,"publicationDate":"2019-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86858262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-07-03DOI: 10.1080/24750573.2019.1633724
A. Poreh, J. Levin
ABSTRACT OBJECTIVE: The present study describes the development of the Cleveland Adaptive Psychopathology Inventory (CAPI), a brief multi-scale personality and psychopathology questionnaire for the screening of common mental health disorders. METHODS: The 118-item questionnaire consists of 10 clinical scales, a brief scale for the screening of substance abuse, and three scales for the assessment of response bias. A sample of 4000 volunteers with and without self-reported medical or mental health conditions was used to assess the psychometric properties of the open source measure including internal consistency, test–retest reliability, and preliminary validity analyses with diagnostic sensitivity and specificity of self-reported psychiatric diagnosis. RESULTS: Internal consistency of the subscales for the normative sample ranged from .568 to .872, with mean inter-item correlations ranging from .161 to .410. The average test-retest across all of the samples ranged from .706 to .872. Finally, sensitivity and specificity (area under the curve) for the subscales with the dependent variables being self-reported diagnosis ranged from .666 to .899. CONCLUSIONS: The preliminary results suggest that the CAPI is a useful tool for clinicians and researchers interested in screening for comorbid psychopathology in both general and clinical populations.
{"title":"The Cleveland Adaptive Psychopathology Inventory: preliminary validity and reliability of a multi-scale personality and psychopathology questionnaire","authors":"A. Poreh, J. Levin","doi":"10.1080/24750573.2019.1633724","DOIUrl":"https://doi.org/10.1080/24750573.2019.1633724","url":null,"abstract":"ABSTRACT OBJECTIVE: The present study describes the development of the Cleveland Adaptive Psychopathology Inventory (CAPI), a brief multi-scale personality and psychopathology questionnaire for the screening of common mental health disorders. METHODS: The 118-item questionnaire consists of 10 clinical scales, a brief scale for the screening of substance abuse, and three scales for the assessment of response bias. A sample of 4000 volunteers with and without self-reported medical or mental health conditions was used to assess the psychometric properties of the open source measure including internal consistency, test–retest reliability, and preliminary validity analyses with diagnostic sensitivity and specificity of self-reported psychiatric diagnosis. RESULTS: Internal consistency of the subscales for the normative sample ranged from .568 to .872, with mean inter-item correlations ranging from .161 to .410. The average test-retest across all of the samples ranged from .706 to .872. Finally, sensitivity and specificity (area under the curve) for the subscales with the dependent variables being self-reported diagnosis ranged from .666 to .899. CONCLUSIONS: The preliminary results suggest that the CAPI is a useful tool for clinicians and researchers interested in screening for comorbid psychopathology in both general and clinical populations.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"21 1","pages":"276 - 284"},"PeriodicalIF":0.7,"publicationDate":"2019-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87517460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-30DOI: 10.1080/24750573.2019.1633007
T. Ayyildiz, Didem Ayyıldız
ABSTRACT AIM: We aimed to explore whether there is difference in terms of Retinal Nerve Fiber Layer (RNFL) thickness, macula thickness and anterior segment structures of the eye between children and adolescents with ADHD and healthy controls. METHOD: Children and adolescents aged 8–16 years who were admitted to the Child Psychiatry outpatient clinic of Ahi Evran University Hospital diagnosed with ADHD constituted the study group. Exclusion criteria included patients who had any systemic/ocular or psychiatric disorder other than ADHD and patients who had any psychopharmacological treatment. Participants in the control group were children and adolescents who applied to the outpatient clinic of Ophthalmology at the same hospital with no chronic medical or psychiatric disorder. Groups were compared in terms of central macular thickness, retinal nerve fibre layer thickness (RNFL), central corneal thickness, corneal diameter, mean corneal radius of curvature, anterior chamber depth, and axial length using Optical Coherence Tomography (OCT) and Optical Biometry. RESULTS: Data obtained from the measurements of 60 eyes of 30 patients with ADHD and 60 eyes of 30 patients of the control group were evaluated. Groups were similar in terms of age and gender. Corneal thickness (p = 0.001) and axial length (p = 0.04) values were significantly higher in ADHD group while the mean corneal curvature radius (p = 0.03) was significantly lower in ADHD group than in controls. No significant difference was observed between groups in terms of RNFL thickness, macular thickness, the corneal diameter, and anterior chamber depth measurements. CONCLUSION: In recent years, the use of OCT in neuropsychiatric diseases has increased the interest in identifying possible biomarkers and the elucidation of neurodegenerative and neurodevelopmental mechanisms that contribute to the nature of these diseases. Differences in the ophthalmic anatomical structures observed between healthy controls and cases with ADHD, which is a neurodevelopmental disorder, need to be supported by longitudinal studies with a larger sample and using OCT in connection with brain imaging.
{"title":"Retinal nerve fiber layer, macular thickness and anterior segment measurements in attention deficit and hyperactivity disorder","authors":"T. Ayyildiz, Didem Ayyıldız","doi":"10.1080/24750573.2019.1633007","DOIUrl":"https://doi.org/10.1080/24750573.2019.1633007","url":null,"abstract":"ABSTRACT AIM: We aimed to explore whether there is difference in terms of Retinal Nerve Fiber Layer (RNFL) thickness, macula thickness and anterior segment structures of the eye between children and adolescents with ADHD and healthy controls. METHOD: Children and adolescents aged 8–16 years who were admitted to the Child Psychiatry outpatient clinic of Ahi Evran University Hospital diagnosed with ADHD constituted the study group. Exclusion criteria included patients who had any systemic/ocular or psychiatric disorder other than ADHD and patients who had any psychopharmacological treatment. Participants in the control group were children and adolescents who applied to the outpatient clinic of Ophthalmology at the same hospital with no chronic medical or psychiatric disorder. Groups were compared in terms of central macular thickness, retinal nerve fibre layer thickness (RNFL), central corneal thickness, corneal diameter, mean corneal radius of curvature, anterior chamber depth, and axial length using Optical Coherence Tomography (OCT) and Optical Biometry. RESULTS: Data obtained from the measurements of 60 eyes of 30 patients with ADHD and 60 eyes of 30 patients of the control group were evaluated. Groups were similar in terms of age and gender. Corneal thickness (p = 0.001) and axial length (p = 0.04) values were significantly higher in ADHD group while the mean corneal curvature radius (p = 0.03) was significantly lower in ADHD group than in controls. No significant difference was observed between groups in terms of RNFL thickness, macular thickness, the corneal diameter, and anterior chamber depth measurements. CONCLUSION: In recent years, the use of OCT in neuropsychiatric diseases has increased the interest in identifying possible biomarkers and the elucidation of neurodegenerative and neurodevelopmental mechanisms that contribute to the nature of these diseases. Differences in the ophthalmic anatomical structures observed between healthy controls and cases with ADHD, which is a neurodevelopmental disorder, need to be supported by longitudinal studies with a larger sample and using OCT in connection with brain imaging.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"88 1","pages":"760 - 764"},"PeriodicalIF":0.7,"publicationDate":"2019-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72798123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-17DOI: 10.1080/24750573.2019.1625587
D. Ozsavci, O. Ozakpinar, M. Cetin, F. Aricioglu
Level of clinical evidence of herbal complementary therapies in psychiatric disorders Derya Ozsavci, Ozlem Bingol Ozakpinar, Mesut Cetin b and Feyza Aricioglu c Department of Biochemistry, School of Pharmacy, Marmara University, Istanbul, Turkey; Psychiatry and Clinical Psychopharmacology, Istanbul, Turkey; Department of Pharmacology and Psychopharmacology Research Unit, School of Pharmacy, Marmara University, Istanbul, Turkey
{"title":"Level of clinical evidence of herbal complementary therapies in psychiatric disorders","authors":"D. Ozsavci, O. Ozakpinar, M. Cetin, F. Aricioglu","doi":"10.1080/24750573.2019.1625587","DOIUrl":"https://doi.org/10.1080/24750573.2019.1625587","url":null,"abstract":"Level of clinical evidence of herbal complementary therapies in psychiatric disorders Derya Ozsavci, Ozlem Bingol Ozakpinar, Mesut Cetin b and Feyza Aricioglu c Department of Biochemistry, School of Pharmacy, Marmara University, Istanbul, Turkey; Psychiatry and Clinical Psychopharmacology, Istanbul, Turkey; Department of Pharmacology and Psychopharmacology Research Unit, School of Pharmacy, Marmara University, Istanbul, Turkey","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"100 1","pages":"239 - 243"},"PeriodicalIF":0.7,"publicationDate":"2019-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73594478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-13DOI: 10.1080/24750573.2019.1627695
Ö. Uygur, H. Uygur
ABSTRACT Clozapine is an antipsychotic drug for the treatment-resistant schizophrenia. Although clozapine is superior to other antipsychotics, it is less common in psychiatric prescriptions due to clozaphobia. Little is known about the use of clozapine during pregnancy and lactation, or its effect on the mother, foetus and baby. Pregnancy category of clozapine is considered to be of relatively reliable category B, while it is recommended to be avoided during breastfeeding. Switching from clozapine to other antipsychotics during breastfeeding may lead to psychotic exacerbations. In this case, low dose of clozapine may need to be added to the antipsychotic treatment initiated during breastfeeding. However, data on the safety of combination antipsychotics during breastfeeding are limited. Psychiatrists, obstetricians and pediatricians should closely monitor with team spirit on such cases, thus drug exposure and side effects of infant are minimized while the mother’s mental health is maintained. We aimed to present the growth and neurodevelopmental outcomes of infant exposed to clozapine during pregnancy and exposed to clozapine plus olanzapine during the lactation period.
{"title":"Neurodevelopmental and growth follow-up of the baby exposed to antipsychotics during pregnancy and lactation: a case report","authors":"Ö. Uygur, H. Uygur","doi":"10.1080/24750573.2019.1627695","DOIUrl":"https://doi.org/10.1080/24750573.2019.1627695","url":null,"abstract":"ABSTRACT Clozapine is an antipsychotic drug for the treatment-resistant schizophrenia. Although clozapine is superior to other antipsychotics, it is less common in psychiatric prescriptions due to clozaphobia. Little is known about the use of clozapine during pregnancy and lactation, or its effect on the mother, foetus and baby. Pregnancy category of clozapine is considered to be of relatively reliable category B, while it is recommended to be avoided during breastfeeding. Switching from clozapine to other antipsychotics during breastfeeding may lead to psychotic exacerbations. In this case, low dose of clozapine may need to be added to the antipsychotic treatment initiated during breastfeeding. However, data on the safety of combination antipsychotics during breastfeeding are limited. Psychiatrists, obstetricians and pediatricians should closely monitor with team spirit on such cases, thus drug exposure and side effects of infant are minimized while the mother’s mental health is maintained. We aimed to present the growth and neurodevelopmental outcomes of infant exposed to clozapine during pregnancy and exposed to clozapine plus olanzapine during the lactation period.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"16 1","pages":"744 - 747"},"PeriodicalIF":0.7,"publicationDate":"2019-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75420327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-11DOI: 10.1080/24750573.2019.1627694
M. Arslan, İshak Aydemir
ABSTRACT OBJECTIVE The purpose of this study is to examine the emotional appetite statuses, eating attitudes and sleep quality of healthcare professionals and the relationships of these with body composition. MATERIAL AND METHODS This is a study which is based on the relational screening model. The population of the study consisted of all personnel working at the Private Çorum and Private Elitpark Hospitals located in the province of Çorum in Turkey. The study included 210 (40%) healthcare professionals from the Private Çorum Hospital and 325 (60%) from the Private Elitpark Hospital, constituting 535 participants in total. The study included a sociodemographic information form that questioned the descriptive and nutrition-related information of the participants, the Emotional Appetite Questionnaire (EMAQ) that determined their emotional appetite statuses, the Eating Attitudes Test (EAT) that determined their eating attitudes and the Pittsburgh Sleep Quality Index (PSQI) that determined their quality of sleep. FINDINGS According to the results that were obtained in the study, the group with the highest BMI values based on their profession consisted of other healthcare personnel (28.6%). The individuals with high negative situation (7.53 ± 1.33, F = 23.746, p = 0.000) and high negative emotion (7.99 ± 1.17, F = 84.444, p = 0.000) appetite levels had higher BMI values. In terms of their emotional appetite statuses, the group with the highest negative emotion (7.05 ± 1.58, F = 3.108, p = 0.001) and negative situation (7.31 ± 1.34, F = 5.188, p = 0.000) scores was “other healthcare personnel”. The personnel with low sleep quality also had high BMI values (83.1%) (χ2 = 8.311, p = 0.040). The group with the highest rate of sleep disorders (66.9%) was nurses (χ2 = 18.661, p = 0.001). The individuals with eating attitude disorders had high BMI values (92.2%) (χ2 = 20.395, p = 0.000). The profession with the highest rate of eating attitude disorders (66.9%) was “other healthcare personnel” (χ2 = 18.661, p = 0.001). The individuals with disrupted sleep quality (53.7%) also had disrupted eating attitudes (χ2 = 17.661, p = 0.001). CONCLUSIONS The participants who had high negative situation and negative emotion scores had higher BMI levels, and the ones with the highest BMI values and highest negative emotion and negative situation values were other healthcare personnel. Individuals with low sleep quality and eating disorders had higher BMI levels, nurses had the highest rates of sleep disorders, and other healthcare personnel had the higher rates of eating disorders. Individuals with disrupted sleep quality were also found to have disrupted eating attitudes.
摘要目的探讨医疗保健专业人员的情绪食欲状态、饮食态度和睡眠质量及其与身体成分的关系。材料与方法本研究基于关系筛选模型。研究对象为位于土耳其Çorum省的私立Çorum和私立Elitpark医院的所有工作人员。该研究包括来自私立Çorum医院的210名(40%)医疗保健专业人员和来自私立Elitpark医院的325名(60%)医疗保健专业人员，共535名参与者。该研究包括一份社会人口统计信息表格，该表格询问了参与者的描述性和营养相关信息，情绪食欲问卷(EMAQ)确定了他们的情绪食欲状态，饮食态度测试(EAT)确定了他们的饮食态度，匹兹堡睡眠质量指数(PSQI)确定了他们的睡眠质量。研究结果显示，按职业划分BMI值最高的人群为其他医护人员(28.6%)。高负性情境(7.53±1.33,F = 23.746, p = 0.000)和高负性情绪(7.99±1.17,F = 84.444, p = 0.000)食欲水平的个体BMI值较高。在情绪食欲状态方面，负性情绪(7.05±1.58,F = 3.108, p = 0.001)和负性情境(7.31±1.34,F = 5.188, p = 0.000)得分最高的是“其他医护人员”。睡眠质量低的人群BMI值也较高(83.1%)(χ2 = 8.311, p = 0.040)。睡眠障碍发生率最高的是护士(66.9%)(χ2 = 18.661, p = 0.001)。饮食态度障碍人群BMI值较高(92.2%)(χ2 = 20.395, p = 0.000)。饮食态度障碍发生率最高的职业是“其他医护人员”(66.9%)(χ2 = 18.661, p = 0.001)。睡眠质量紊乱者(53.7%)饮食态度紊乱(χ2 = 17.661, p = 0.001)。结论消极情境和消极情绪得分高的被试BMI水平较高，而BMI值最高、消极情绪和消极情境得分最高的是其他医护人员。睡眠质量低和饮食失调的个体有较高的BMI水平，护士有最高的睡眠失调率，其他医护人员有较高的饮食失调率。研究发现，睡眠质量不佳的人也会影响他们的饮食态度。
{"title":"Relationship between emotional appetite, eating attitudes, sleep quality, and body mass index in healthcare workers: a multi-centre study","authors":"M. Arslan, İshak Aydemir","doi":"10.1080/24750573.2019.1627694","DOIUrl":"https://doi.org/10.1080/24750573.2019.1627694","url":null,"abstract":"ABSTRACT OBJECTIVE The purpose of this study is to examine the emotional appetite statuses, eating attitudes and sleep quality of healthcare professionals and the relationships of these with body composition. MATERIAL AND METHODS This is a study which is based on the relational screening model. The population of the study consisted of all personnel working at the Private Çorum and Private Elitpark Hospitals located in the province of Çorum in Turkey. The study included 210 (40%) healthcare professionals from the Private Çorum Hospital and 325 (60%) from the Private Elitpark Hospital, constituting 535 participants in total. The study included a sociodemographic information form that questioned the descriptive and nutrition-related information of the participants, the Emotional Appetite Questionnaire (EMAQ) that determined their emotional appetite statuses, the Eating Attitudes Test (EAT) that determined their eating attitudes and the Pittsburgh Sleep Quality Index (PSQI) that determined their quality of sleep. FINDINGS According to the results that were obtained in the study, the group with the highest BMI values based on their profession consisted of other healthcare personnel (28.6%). The individuals with high negative situation (7.53 ± 1.33, F = 23.746, p = 0.000) and high negative emotion (7.99 ± 1.17, F = 84.444, p = 0.000) appetite levels had higher BMI values. In terms of their emotional appetite statuses, the group with the highest negative emotion (7.05 ± 1.58, F = 3.108, p = 0.001) and negative situation (7.31 ± 1.34, F = 5.188, p = 0.000) scores was “other healthcare personnel”. The personnel with low sleep quality also had high BMI values (83.1%) (χ2 = 8.311, p = 0.040). The group with the highest rate of sleep disorders (66.9%) was nurses (χ2 = 18.661, p = 0.001). The individuals with eating attitude disorders had high BMI values (92.2%) (χ2 = 20.395, p = 0.000). The profession with the highest rate of eating attitude disorders (66.9%) was “other healthcare personnel” (χ2 = 18.661, p = 0.001). The individuals with disrupted sleep quality (53.7%) also had disrupted eating attitudes (χ2 = 17.661, p = 0.001). CONCLUSIONS The participants who had high negative situation and negative emotion scores had higher BMI levels, and the ones with the highest BMI values and highest negative emotion and negative situation values were other healthcare personnel. Individuals with low sleep quality and eating disorders had higher BMI levels, nurses had the highest rates of sleep disorders, and other healthcare personnel had the higher rates of eating disorders. Individuals with disrupted sleep quality were also found to have disrupted eating attitudes.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"14 1","pages":"346 - 353"},"PeriodicalIF":0.7,"publicationDate":"2019-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80139199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-04DOI: 10.1080/24750573.2019.1625184
Lyang Huh, B. Lee
ABSTRACT Purpose: The objective of this retrospective chart review study was to evaluate the long-term efficacy and tolerability of blonanserin treatment in individuals with schizophrenia. Patients and methods: We collected data from 28 (56%) antipsychotic-naïve subjects with first-episode (FE) schizophrenia and 22 subjects with relapsed schizophrenia treated with blonanserin. We investigated psychiatric hospitalization and medication discontinuation rates, Positive and Negative Syndrome Scale (PANSS) scores, Clinical Global Impression–Severity (CGI-S) scale scores, body mass index (BMI) at baseline to endpoint and laboratory tests including serum prolactin, total cholesterol (TC), low-density lipoproteins (LDL), high-density lipoproteins (HDL), triglycerides (TG), and glucose. Additionally, we measured the differences between the two groups and overall changes in levels. Results: Thirty-one subjects received blonanserin for 3 years. Significant improvements in psychiatric symptoms from baseline to endpoint were observed individuals with schizophrenia who received blonanserin treatment. There were remarkable changes in PANSS and CGI-S scores between baseline and those measured after 3 years (p < .01) in both groups; the FE schizophrenia group demonstrated better improvement as reflected by clinical changes assessments. Compared to baseline values, the endpoint measurements showed no statistical differences in terms of serum prolactin, glucose, or LDL and HDL cholesterol (p > .05) in both groups. After 3 years of treatment, there was a statistically significant increase in TC and TG with only a minimal increase in BMI (p < .05). However, there were no statistical differences between the two groups. Conclusion: Blonanserin is useful for the maintenance treatment of schizophrenia due to its therapeutic efficacy; moreover, it does not induce hyperprolactinaemia, significant weight gain, or cause problematic endocrine effects. Its strength might be attributed to its unique pharmacological properties.
{"title":"Comparison of long-term efficacy and safety of blonanserin treatment in individuals with first-episode and relapsed schizophrenia: a 3-year retrospective study","authors":"Lyang Huh, B. Lee","doi":"10.1080/24750573.2019.1625184","DOIUrl":"https://doi.org/10.1080/24750573.2019.1625184","url":null,"abstract":"ABSTRACT Purpose: The objective of this retrospective chart review study was to evaluate the long-term efficacy and tolerability of blonanserin treatment in individuals with schizophrenia. Patients and methods: We collected data from 28 (56%) antipsychotic-naïve subjects with first-episode (FE) schizophrenia and 22 subjects with relapsed schizophrenia treated with blonanserin. We investigated psychiatric hospitalization and medication discontinuation rates, Positive and Negative Syndrome Scale (PANSS) scores, Clinical Global Impression–Severity (CGI-S) scale scores, body mass index (BMI) at baseline to endpoint and laboratory tests including serum prolactin, total cholesterol (TC), low-density lipoproteins (LDL), high-density lipoproteins (HDL), triglycerides (TG), and glucose. Additionally, we measured the differences between the two groups and overall changes in levels. Results: Thirty-one subjects received blonanserin for 3 years. Significant improvements in psychiatric symptoms from baseline to endpoint were observed individuals with schizophrenia who received blonanserin treatment. There were remarkable changes in PANSS and CGI-S scores between baseline and those measured after 3 years (p < .01) in both groups; the FE schizophrenia group demonstrated better improvement as reflected by clinical changes assessments. Compared to baseline values, the endpoint measurements showed no statistical differences in terms of serum prolactin, glucose, or LDL and HDL cholesterol (p > .05) in both groups. After 3 years of treatment, there was a statistically significant increase in TC and TG with only a minimal increase in BMI (p < .05). However, there were no statistical differences between the two groups. Conclusion: Blonanserin is useful for the maintenance treatment of schizophrenia due to its therapeutic efficacy; moreover, it does not induce hyperprolactinaemia, significant weight gain, or cause problematic endocrine effects. Its strength might be attributed to its unique pharmacological properties.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"1 1","pages":"399 - 406"},"PeriodicalIF":0.7,"publicationDate":"2019-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88403406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-04DOI: 10.1080/24750573.2019.1626067
Seon-Cheol Park, Eun-Young Jang, Gyung-Mee Kim, A. Avasthi, S. Grover, A. J. Tanra, Takahiro A. Kato, K. Chee, M. Chong, A. Javed, Chay-Hoon Tan, N. Sartorius, N. Shinfuku, Y. Park
ABSTRACT OBJECTIVE: We aimed to present the scalability and cut-off score for the presence of aggression on the Brief Psychiatric Rating Scale-Excited Component (BPRS-EC) in schizophrenia patients. METHODS: From the Research on Asian Psychotropic Prescription Patterns for Antipsychotics, 1,438 Asian patients with schizophrenia were recruited in present study. The Mokken analysis was used to evaluate scalability of the BPRS-EC. The receiver operating characteristic (ROC) curve was used to establish the optimal cut-off score for the presence of aggression on the BPRS-6 in schizophrenia patients. RESULTS: The Mokken model presented that the scalability of the BPRS-EC was considered to have a strong “unidimensionality” (coefficient of scalability = 0.57). The ROC curve showed that, with the cut-off score of 5, the total score on the BPRS-EC distinguished the absence and presence of aggression in schizophrenia patients. CONCLUSION: The BPRS-EC can be used as a supplementary scale for evaluating aggression in patients with schizophrenia.
{"title":"Establishing the cut-off score for aggression on the Brief Psychiatric Rating Scale-Excited Component (BPRS-EC) in schizophrenia patients","authors":"Seon-Cheol Park, Eun-Young Jang, Gyung-Mee Kim, A. Avasthi, S. Grover, A. J. Tanra, Takahiro A. Kato, K. Chee, M. Chong, A. Javed, Chay-Hoon Tan, N. Sartorius, N. Shinfuku, Y. Park","doi":"10.1080/24750573.2019.1626067","DOIUrl":"https://doi.org/10.1080/24750573.2019.1626067","url":null,"abstract":"ABSTRACT OBJECTIVE: We aimed to present the scalability and cut-off score for the presence of aggression on the Brief Psychiatric Rating Scale-Excited Component (BPRS-EC) in schizophrenia patients. METHODS: From the Research on Asian Psychotropic Prescription Patterns for Antipsychotics, 1,438 Asian patients with schizophrenia were recruited in present study. The Mokken analysis was used to evaluate scalability of the BPRS-EC. The receiver operating characteristic (ROC) curve was used to establish the optimal cut-off score for the presence of aggression on the BPRS-6 in schizophrenia patients. RESULTS: The Mokken model presented that the scalability of the BPRS-EC was considered to have a strong “unidimensionality” (coefficient of scalability = 0.57). The ROC curve showed that, with the cut-off score of 5, the total score on the BPRS-EC distinguished the absence and presence of aggression in schizophrenia patients. CONCLUSION: The BPRS-EC can be used as a supplementary scale for evaluating aggression in patients with schizophrenia.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"26 1","pages":"407 - 410"},"PeriodicalIF":0.7,"publicationDate":"2019-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81718262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-06-03DOI: 10.1080/24750573.2019.1605665
M. Erdinc, E. Uyar, I. Kelle, H. Akkoç
ABSTRACT OBJECTIVE: In pain management, alternative medications are necessary due to the development of tolerance to traditional opioid analgesics. Literature data suggest that N-methyl-D-aspartate (NMDA) receptor antagonizing drugs can induce antinociception, and can reduce the opioid requirement. Ketamine is a non-competitive NMDA receptor antagonist drug and has well-known antinociceptive properties. The drug acts not only on NMDA receptors but also has effects on the monoaminergic system and non-NMDA glutamatergic receptors which have vital roles in the regulation of pain. This study was conducted to investigate the serotonergic and glutamatergic involvement in low-dose ketamine (20 mg/kg) analgesia in mice. METHOD: The effects of serotonin were suppressed with two different ways; either the serotonin was depleted with p-chlorophenylalanine (pCPA, 150 mg/kg/d; 4 days) or the serotonin receptors were blocked with methiothepin (0.1 mg/kg), and α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors were antagonized with GYKI-52466 (20 mg/kg). Fluoxetine (20 mg/kg; 7 days) was used to increase the serotoninergic activity. We used a hotplate (HP) test to measure pain reaction latencies. Furthermore, we tested sustained analgesic effects of ketamine for six consecutive times (1-hour break between each test). RESULTS: In our experiment, ketamine treatment increased pain reaction latencies, yet it failed to increase the latencies when combined with antiserotonergic drugs, e.g. pCPA and methiothepin. The latencies were increased with AMPA receptor blockade, yet ketamine did not increase the analgesic effect of the AMPA receptor antagonist, i.e. GYKI-52466. In consecutive tests, ketamine was effective for 5 h, and the peak effect was seen at the 3rd-hour test. CONCLUSION: Our data suggest that the activity of the serotonergic system and AMPA receptors are necessary for ketamine to produce antinociceptive effects. In pain management, ketamine can offer an alternative option to traditional analgesics and may be useful to reduce opioid tolerance.
{"title":"Anti-nociceptive effects of low dose ketamine in mice may be mediated by the serotonergic systems","authors":"M. Erdinc, E. Uyar, I. Kelle, H. Akkoç","doi":"10.1080/24750573.2019.1605665","DOIUrl":"https://doi.org/10.1080/24750573.2019.1605665","url":null,"abstract":"ABSTRACT OBJECTIVE: In pain management, alternative medications are necessary due to the development of tolerance to traditional opioid analgesics. Literature data suggest that N-methyl-D-aspartate (NMDA) receptor antagonizing drugs can induce antinociception, and can reduce the opioid requirement. Ketamine is a non-competitive NMDA receptor antagonist drug and has well-known antinociceptive properties. The drug acts not only on NMDA receptors but also has effects on the monoaminergic system and non-NMDA glutamatergic receptors which have vital roles in the regulation of pain. This study was conducted to investigate the serotonergic and glutamatergic involvement in low-dose ketamine (20 mg/kg) analgesia in mice. METHOD: The effects of serotonin were suppressed with two different ways; either the serotonin was depleted with p-chlorophenylalanine (pCPA, 150 mg/kg/d; 4 days) or the serotonin receptors were blocked with methiothepin (0.1 mg/kg), and α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors were antagonized with GYKI-52466 (20 mg/kg). Fluoxetine (20 mg/kg; 7 days) was used to increase the serotoninergic activity. We used a hotplate (HP) test to measure pain reaction latencies. Furthermore, we tested sustained analgesic effects of ketamine for six consecutive times (1-hour break between each test). RESULTS: In our experiment, ketamine treatment increased pain reaction latencies, yet it failed to increase the latencies when combined with antiserotonergic drugs, e.g. pCPA and methiothepin. The latencies were increased with AMPA receptor blockade, yet ketamine did not increase the analgesic effect of the AMPA receptor antagonist, i.e. GYKI-52466. In consecutive tests, ketamine was effective for 5 h, and the peak effect was seen at the 3rd-hour test. CONCLUSION: Our data suggest that the activity of the serotonergic system and AMPA receptors are necessary for ketamine to produce antinociceptive effects. In pain management, ketamine can offer an alternative option to traditional analgesics and may be useful to reduce opioid tolerance.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"3 1","pages":"252 - 256"},"PeriodicalIF":0.7,"publicationDate":"2019-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72904285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-05-21DOI: 10.1080/24750573.2019.1619258
F. Çetin, H. Güler, S. Ersoy, S. Türkoğlu
ABSTRACT OBJECTIVES: The aim of this study was to determine the order of improvement in response inhibition, interference capacity, and processing speed in the Stroop test after starting methylphenidate treatment in children with ADHD. METHODS: This study included a total of 52 children aged 7–16 years who were diagnosed with combined-type ADHD for the first time and who began to use methylphenidate treatment. The Stroop test was applied to each subject at least 3 times (before treatment and at the first and second months of treatment) in the follow-up visits. RESULTS: The participants completed the fifth section of the Stroop test at a median duration of42.09 sec (quartiles: 35.58–54.0 sec) before treatment, while the median duration was 34.49 sec (quartiles: 27.43–34.48 sec) at the first month of treatment and 32.18 sec (quartiles: 26.97–32.18 sec) at the second month of treatment. The task completion duration showed a statistically significant improvement from the first month of treatment (p < 0.001). When the participants were compared in terms of the number of errors and corrections they made in the fifth section of the Stroop test, there was no significant difference between pretreatment measurements and post-treatment first month measurements (p > 0.05). The number of errors and corrections were statistically significantly lower in the second month of treatment compared to pretreatment and 1st mont of the treatment (p < 0.05). CONCLUSIONS: This study demonstrated that processing speed, response inhibition, and interference capacity assessed by the Stroop test improved with methylphenidate treatment in children with ADHD. This study is the first study to show that these improvements occur in a certain order over time.
{"title":"Processing speed may improve earlier than response inhibition/ interferens in children with ADHD-combined type receiving methylphenidate: a single-center study","authors":"F. Çetin, H. Güler, S. Ersoy, S. Türkoğlu","doi":"10.1080/24750573.2019.1619258","DOIUrl":"https://doi.org/10.1080/24750573.2019.1619258","url":null,"abstract":"ABSTRACT OBJECTIVES: The aim of this study was to determine the order of improvement in response inhibition, interference capacity, and processing speed in the Stroop test after starting methylphenidate treatment in children with ADHD. METHODS: This study included a total of 52 children aged 7–16 years who were diagnosed with combined-type ADHD for the first time and who began to use methylphenidate treatment. The Stroop test was applied to each subject at least 3 times (before treatment and at the first and second months of treatment) in the follow-up visits. RESULTS: The participants completed the fifth section of the Stroop test at a median duration of42.09 sec (quartiles: 35.58–54.0 sec) before treatment, while the median duration was 34.49 sec (quartiles: 27.43–34.48 sec) at the first month of treatment and 32.18 sec (quartiles: 26.97–32.18 sec) at the second month of treatment. The task completion duration showed a statistically significant improvement from the first month of treatment (p < 0.001). When the participants were compared in terms of the number of errors and corrections they made in the fifth section of the Stroop test, there was no significant difference between pretreatment measurements and post-treatment first month measurements (p > 0.05). The number of errors and corrections were statistically significantly lower in the second month of treatment compared to pretreatment and 1st mont of the treatment (p < 0.05). CONCLUSIONS: This study demonstrated that processing speed, response inhibition, and interference capacity assessed by the Stroop test improved with methylphenidate treatment in children with ADHD. This study is the first study to show that these improvements occur in a certain order over time.","PeriodicalId":20847,"journal":{"name":"Psychiatry and Clinical Psychopharmacology","volume":"29 1","pages":"737 - 743"},"PeriodicalIF":0.7,"publicationDate":"2019-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73640379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：